This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Vifor Pharma Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

16.3%

Groei van de winst

16.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	14.1%
Inkomstengroei	7.5%
Rendement op eigen vermogen	6.7%
Nettomarge	8.1%
Laatste winstupdate	31 Dec 2021

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Vifor Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

LSE:0RPD Opbrengsten, kosten en inkomsten (CHF Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Dec 21	1,812	147	544	225
30 Jun 21	1,753	213	542	155
31 Mar 21	1,757	176	551	175
31 Dec 20	1,762	139	560	194
30 Jun 20	1,709	93	553	249
31 Mar 20	1,732	101	563	231
31 Dec 19	1,754	108	573	212
30 Sep 19	1,845	129	588	226
30 Jun 19	1,784	100	576	224
31 Mar 19	1,711	126	571	215
31 Dec 18	1,639	152	567	206
30 Sep 18	1,571	157	571	199
30 Jun 18	1,504	162	576	191
31 Mar 18	1,441	98	561	188
31 Dec 17	1,378	34	546	185
30 Sep 17	1,345	26	544	173
30 Jun 17	1,312	18	543	162
31 Mar 17	1,283	82	503	142
31 Dec 16	1,254	147	464	122
30 Sep 16	1,944	218	525	84
30 Jun 16	2,635	290	587	46
31 Mar 16	3,265	295	654	23
31 Dec 15	3,896	301	722	0

Kwaliteitswinsten: 0RPD heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (8.1%) 0RPD } zijn hoger dan vorig jaar (7.9%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 0RPD is de afgelopen 5 jaar met 16.3% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 0RPD over het afgelopen jaar ( 5.7% ) ligt onder het 5-jarig gemiddelde ( 16.3% per jaar).

Winst versus industrie: De winstgroei 0RPD over het afgelopen jaar ( 5.7% ) overtrof de Pharmaceuticals -sector 4.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 6.7% ) van 0RPD wordt als laag beschouwd.

This company listing is no longer active

Vifor Pharma Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

High number of new directors

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Investor sentiment improved over the past week

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Chief Executive Officer Stefan Schulze has left the company

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Independent Director has left the company

Independent Director has left the company

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Upcoming dividend of CHF2.00 per share

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Revenue misses expectations

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

New 90-day low: CHF113

New 90-day low: CHF118

Vifor Pharma Announces Board Changes

New 90-day high: CHF137

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Market bids up stock over the past week

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

New 90-day low: CHF120

New 90-day low: CHF122

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

New 90-day low - CHF124

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

New 90-day low - CHF134

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden